Andrea Stojakovic finished her PhD in Medical sciences at Australian National University, Canberra in 2014. Her PhD dissertation was on the understanding of long-term effect of chronic inflammation and high-fat diet on degeneration of dopamine neurons in substantia nigra. She is currently working as a Research Associate at Mayo Clinic, Rochester, MN. Her research interests are focused on neurodegenerative diseases such as Alzheimer`s disease, Huntington`s disease, Parkinson`s disease, and neurodegeneration caused by aging. Her current work at Mayo Clinic resulted in a robust drug discovery for AD and it will enter phase I clinical trial in near future. They identified a member of tricyclic pyrone molecules, code name CP2, as a lead compound that prevented aggregation of misfolded proteins and restored altered cellular, metabolic and cognitive functions in different mice models of AD. Findings from this work are recently published in Communications Biology.